IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v41y2023i4d10.1007_s40273-023-01241-2.html
   My bibliography  Save this article

Modelling the Cost-Effectiveness of Diagnostic Tests

Author

Listed:
  • Tristan Snowsill

    (University of Exeter)

Abstract

Diagnostic tests are used to determine whether a disease or condition is present or absent in a patient, who will typically be suspected of having the disease or condition due to symptoms or clinical signs. Economic evaluations of diagnostic tests (e.g. cost-effectiveness analyses) can be used to determine whether a test produces sufficient benefit to justify its cost. Evidence on the benefits conferred by a test is often restricted to its accuracy, which means mathematical models are required to estimate the impact of a test on outcomes that matter to patients and health payers. It is important to realise the case for introducing a new test may not be restricted to its accuracy, but extend to factors such as time to diagnosis and acceptability for patients. These and other considerations may mean the common modelling approach, the decision tree, is inappropriate for underpinning an economic evaluation. There are no consensus guidelines on how economic evaluations of diagnostic tests should be conducted—this article attempts to explore the common challenges encountered in economic evaluations, suggests solutions to those challenges, and identifies some areas where further methodological work may be necessary.

Suggested Citation

  • Tristan Snowsill, 2023. "Modelling the Cost-Effectiveness of Diagnostic Tests," PharmacoEconomics, Springer, vol. 41(4), pages 339-351, April.
    • Handle: RePEc:spr:pharme:v:41:y:2023:i:4:d:10.1007_s40273-023-01241-2
    DOI: 10.1007/s40273-023-01241-2
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-023-01241-2
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40273-023-01241-2?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Mohan V. Bala & Gary A. Zarkin, 2000. "Are QALYs an appropriate measure for valuing morbidity in acute diseases?," Health Economics, John Wiley & Sons, Ltd., vol. 9(2), pages 177-180, March.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. David Bardey & Philippe de Donder & Vera Zaporozhets, 2024. "Economic Incentives to Develop and to Use Diagnostic Tests - A Literature Review," Working Papers hal-04472497, HAL.
    2. David Bardey & Philippe de Donder & Vera Zaporozhets, 2024. "The Health Technology Assessment Approach of the Economic Value of Diagnostic Tests - A Literature Review," Working Papers hal-04472485, HAL.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Greenberg, Dan & Bakhai, Ameet & Neumann, Peter J. & Cohen, David J., 2004. "Willingness to pay for avoiding coronary restenosis and repeat revascularization: results from a contingent valuation study," Health Policy, Elsevier, vol. 70(2), pages 207-216, November.
    2. Wagner, Todd H. & Hu, Teh-wei & Duenas, Grace V. & Kaplan, Celia P. & Nguyen, Bang H. & Pasick, Rena J., 2001. "Does willingness to pay vary by race/ethnicity? An analysis using mammography among low-income women," Health Policy, Elsevier, vol. 58(3), pages 275-288, December.
    3. John Slof, 2012. "Cost-effectiveness analysis of early versus non-early intervention in acute migraine based on evidence from the ‘Act when Mild’ study," Applied Health Economics and Health Policy, Springer, vol. 10(3), pages 201-215, May.
    4. A. Freeman, 2006. "Valuing Environmental Health Effects – An Economic Perspective," Environmental & Resource Economics, Springer;European Association of Environmental and Resource Economists, vol. 34(3), pages 347-363, July.
    5. Birch, Stephen & Gafni, Amiram, 2003. "Economics and the evaluation of health care programmes: generalisability of methods and implications for generalisability of results," Health Policy, Elsevier, vol. 64(2), pages 207-219, May.
    6. F. Reed Johnson & Juan Marcos Gonzalez & John J. Sheehan & Shelby D. Reed, 2023. "How Much Better is Faster? Value Adjustments for Health-Improvement Sequences," PharmacoEconomics, Springer, vol. 41(8), pages 845-856, August.
    7. Hammitt, James K. & Haninger, Kevin, 2017. "Valuing nonfatal health risk as a function of illness severity and duration: Benefit transfer using QALYs," Journal of Environmental Economics and Management, Elsevier, vol. 82(C), pages 17-38.
    8. Morteza Chalak & Veronique Florec & Atakelty Hailu & Fiona Gibson & David Pannell, 2017. "Integrating non-market values in economic analyses of flood mitigation: a case study of the Brown Hill and Keswick creeks catchment in Adelaide," Working Papers 256513, University of Western Australia, School of Agricultural and Resource Economics.
    9. George Van Houtven & John Powers & Amber Jessup & Jui‐Chen Yang, 2006. "Valuing avoided morbidity using meta‐regression analysis: what can health status measures and QALYs tell us about WTP?," Health Economics, John Wiley & Sons, Ltd., vol. 15(8), pages 775-795, August.
    10. F. Reed Johnson, 2012. "Why Not Real Economics?," PharmacoEconomics, Springer, vol. 30(2), pages 127-131, February.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:41:y:2023:i:4:d:10.1007_s40273-023-01241-2. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.